ECSP23076276A - Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 - Google Patents
Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1Info
- Publication number
- ECSP23076276A ECSP23076276A ECSENADI202376276A ECDI202376276A ECSP23076276A EC SP23076276 A ECSP23076276 A EC SP23076276A EC SENADI202376276 A ECSENADI202376276 A EC SENADI202376276A EC DI202376276 A ECDI202376276 A EC DI202376276A EC SP23076276 A ECSP23076276 A EC SP23076276A
- Authority
- EC
- Ecuador
- Prior art keywords
- antigen
- methods
- binding fragment
- subcutaneous administration
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a métodos para tratar el cáncer en un paciente, que comprenden administrar por vía subcutánea un antagonista de PD-1, p. ej., un anticuerpo anti-PD-1 o fragmento de unión a antígeno del mismo (p. ej., en cantidades específicas al paciente. En algunas realizaciones, la administración se produce aproximadamente cada tres semanas. En algunas realizaciones, la cantidad de anticuerpo anti-PD-1 o fragmento de unión al antígeno del mismo es de aproximadamente 280 mg a aproximadamente 450 mg. En determinadas realizaciones, el antagonista de PD-1 es pembrolizumab o un fragmento de unión al antígeno del mismo. También se proporcionan composiciones y kits formulados para administración subcutánea que comprenden una dosis de un anticuerpo anti-PD-1, o fragmento de unión al antígeno del mismo, y sus usos para tratar el cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172299P | 2021-04-08 | 2021-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23076276A true ECSP23076276A (es) | 2023-11-30 |
Family
ID=83546458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202376276A ECSP23076276A (es) | 2021-04-08 | 2023-10-06 | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20250074983A1 (es) |
| EP (1) | EP4320163A4 (es) |
| JP (1) | JP2024513247A (es) |
| KR (1) | KR20230170029A (es) |
| CN (1) | CN117279952A (es) |
| AR (1) | AR125296A1 (es) |
| AU (1) | AU2022254960A1 (es) |
| BR (1) | BR112023020867A2 (es) |
| CA (1) | CA3214617A1 (es) |
| CL (1) | CL2023002976A1 (es) |
| CO (1) | CO2023013273A2 (es) |
| CR (1) | CR20230473A (es) |
| DO (1) | DOP2023000216A (es) |
| EC (1) | ECSP23076276A (es) |
| GE (1) | GEAP202416385A (es) |
| IL (1) | IL307430A (es) |
| JO (1) | JOP20230243A1 (es) |
| MX (1) | MX2023011857A (es) |
| PE (1) | PE20240051A1 (es) |
| TW (1) | TW202305009A (es) |
| WO (1) | WO2022216580A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120053667A (zh) | 2019-03-25 | 2025-05-30 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| WO2025140467A1 (zh) * | 2023-12-29 | 2025-07-03 | 上海复宏汉霖生物技术股份有限公司 | 稳定的高浓度抗pd-1抗体药物制剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2004218354B2 (en) | 2003-03-05 | 2009-10-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| EP2981821B2 (en) | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CA3065836A1 (en) * | 2017-06-05 | 2018-12-13 | The Council Of The Queensland Institute Of Medical Research | Agents for cancer therapy or prophylaxis and uses therefor |
| BR112020015915A8 (pt) | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| US12371683B2 (en) | 2018-07-25 | 2025-07-29 | Alteogen Inc. | Hyaluronidase variants and pharmaceutical composition comprising the same |
| WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| CN120053667A (zh) * | 2019-03-25 | 2025-05-30 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
-
2022
- 2022-04-01 TW TW111112795A patent/TW202305009A/zh unknown
- 2022-04-04 WO PCT/US2022/023250 patent/WO2022216580A1/en not_active Ceased
- 2022-04-04 IL IL307430A patent/IL307430A/en unknown
- 2022-04-04 EP EP22785209.2A patent/EP4320163A4/en active Pending
- 2022-04-04 BR BR112023020867A patent/BR112023020867A2/pt unknown
- 2022-04-04 AU AU2022254960A patent/AU2022254960A1/en active Pending
- 2022-04-04 CN CN202280033638.8A patent/CN117279952A/zh active Pending
- 2022-04-04 KR KR1020237038583A patent/KR20230170029A/ko active Pending
- 2022-04-04 JP JP2023561333A patent/JP2024513247A/ja active Pending
- 2022-04-04 PE PE2023002821A patent/PE20240051A1/es unknown
- 2022-04-04 AR ARP220100836A patent/AR125296A1/es unknown
- 2022-04-04 US US18/554,213 patent/US20250074983A1/en active Pending
- 2022-04-04 MX MX2023011857A patent/MX2023011857A/es unknown
- 2022-04-04 GE GEAP202416385A patent/GEAP202416385A/en unknown
- 2022-04-04 CA CA3214617A patent/CA3214617A1/en active Pending
- 2022-04-04 CR CR20230473A patent/CR20230473A/es unknown
-
2023
- 2023-10-04 CL CL2023002976A patent/CL2023002976A1/es unknown
- 2023-10-05 DO DO2023000216A patent/DOP2023000216A/es unknown
- 2023-10-05 CO CONC2023/0013273A patent/CO2023013273A2/es unknown
- 2023-10-06 EC ECSENADI202376276A patent/ECSP23076276A/es unknown
- 2023-10-08 JO JOJO/P/2023/0243A patent/JOP20230243A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250074983A1 (en) | 2025-03-06 |
| AU2022254960A1 (en) | 2023-11-23 |
| CN117279952A (zh) | 2023-12-22 |
| JP2024513247A (ja) | 2024-03-22 |
| CR20230473A (es) | 2023-11-30 |
| AU2022254960A9 (en) | 2023-11-30 |
| CL2023002976A1 (es) | 2024-06-28 |
| PE20240051A1 (es) | 2024-01-09 |
| JOP20230243A1 (ar) | 2023-10-08 |
| WO2022216580A1 (en) | 2022-10-13 |
| EP4320163A1 (en) | 2024-02-14 |
| CO2023013273A2 (es) | 2023-10-30 |
| AR125296A1 (es) | 2023-07-05 |
| CA3214617A1 (en) | 2022-10-13 |
| GEAP202416385A (en) | 2024-02-26 |
| BR112023020867A2 (pt) | 2023-12-12 |
| TW202305009A (zh) | 2023-02-01 |
| DOP2023000216A (es) | 2023-11-30 |
| MX2023011857A (es) | 2023-10-19 |
| EP4320163A4 (en) | 2025-03-05 |
| IL307430A (en) | 2023-12-01 |
| KR20230170029A (ko) | 2023-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| MX2024007358A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| CL2023003357A1 (es) | Régimen de dosis para terapia combinada dirigida a dll3 y pd-1 | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| CL2025003511A1 (es) | Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| BR112023016320A2 (pt) | Composição terapêutica e método de combinação de imunoterapia multiplex com vacina contra câncer para tratamento de câncer | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| CL2024003729A1 (es) | Terapia combinada de agente activo anti-pd-1, agente activo anti-tim-3 y agente activo anti-lag-3 para tratar cáncer. | |
| MX2025005378A (es) | Metodos para el tratamiento de enfermedades cardiovasculares | |
| MX2024006799A (es) | Metodos para el tratamiento de cáncer con prame positivo. | |
| CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
| DOP2025000008A (es) | Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
| AR130745A1 (es) | Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| PY2013134A (es) | Métodos para el tratamiento de enfermedades relacionadas con tnfa | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| MX2022001153A (es) | Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab. | |
| AR124527A1 (es) | Métodos de tratamiento de tumores | |
| PE20250161A1 (es) | Dosis para tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 en pacientes mayores | |
| CR20220041A (es) | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab | |
| AR133823A1 (es) | Métodos de tratamiento que utilizan agentes de unión a epcam y cd137 en combinación con antagonistas de unión al eje pd-1 |